Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Wholesale Dealer President Deeply Sorry for Letting Fake Harvoni into Supply Chain
The president of a wholesale dealer who “unknowingly” introduced fake Harvoni (ledipasvir + sofosbuvir) into the Japanese drug supply chain finally met the press on March 23, apologizing for the fiasco and revealing how he purchased what was later found…
To read the full story
Related Article
- Tokyo Govt Orders 2 “Cash-and-Carry” Dealers to Suspend Business
April 14, 2017
- 2 Kansai Medico Pharmacy Outlets Ordered to Suspend Biz
March 17, 2017
- Tokyo, Osaka Govts Issue Biz Improvement Order to Dealers over Fake Harvoni
March 14, 2017
- 3 Kansai Medico Pharmacies Slapped with Biz Improvement Order over Fake Harvoni
March 7, 2017
- MHLW Mulls Administrative Penalties, Tighter Regulations after Counterfeit Harvoni Case
February 14, 2017
- MHLW Wraps Up Probe into Fake Harvoni after Distribution Routes “Most Likely” Identified
February 2, 2017
- MHLW Pins Down Distribution Routes for Harvoni Counterfeits; Composition of Fake Pills Identified
February 1, 2017
- Kansai Medico Used Non-Official Harvoni Dealer for Cheaper Price
January 25, 2017
- Counterfeit Harvoni Found in Tokyo Too, Route Identified for a Nara Bottle
January 24, 2017
- Counterfeit Harvoni Discovered in Nara Pharmacy, MHLW Investigating Route of Entry into Distribution
January 18, 2017
BUSINESS
- Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
- Enhertu Snags EU Approval in HER2 Positive Solid Tumors
June 30, 2026
- Datroway Grabs Positive CHMP Opinion in 1st-Line TNBC
June 30, 2026
- Tanabe Gets Thai Approval for Diabetes Drug Canalia
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…